ArticleBlood2026
Platelet Drp1 phosphorylation provides a platform for immune-based platelet function testing.
Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
abstractDynamin-related protein 1 (Drp1) is an abundant platelet protein best known for its function in mitochondrial fission. However, little is known about how Drp1 is controlled during platelet activation. While evaluating signaling pathways leading to phosphorylation of Drp1 in platelets, we identified a phosphorylation network wherein activation of G protein-coupled receptors or immunoreceptor tyrosine-based activation motif (ITAM)/hemITAM receptors resulted in phosphorylation of Ser616-Drp1 via p38. These signaling mechanisms were reinforced by ADP- and thromboxane A2 (TxA2)-mediated amplification pathways. In contrast, exposure of platelets to pacifying agents such as prostaglandin E1 or nitric oxide resulted in Ser637-Drp1 phosphorylation by cyclic nucleotide-dependent protein kinases. This unique circuitry was leveraged to develop immune-based platelet function assays, enabling enzyme-linked immunosorbent assay and lateral flow assay formats. Compared with standard platelet function assays, Drp1 phosphorylation remained robust in whole blood samples following agitation or extended incubation, and samples could be frozen for batching. As proof of principle for antiplatelet testing, phospho-Drp1 measurements were obtained at baseline, during a week of aspirin or clopidogrel exposure, and during a week of washout. Arachidonic acid-induced Ser616-Drp1 phosphorylation following aspirin ingestion demonstrated an enhanced dynamic range with improved linearity relative to light transmission aggregometry and an improved signal-to-noise ratio relative to the VerifyNow aspirin test. Ser637-Drp1 phosphorylation enabled sensitive detection of clopidogrel ingestion. These studies elucidate the unique signaling circuit controlling Drp1 phosphorylation in platelets and validate the approach of using detailed knowledge of platelet signaling pathways to develop high-fidelity immune-based assays to monitor platelet function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.